Frankfurt - Delayed Quote EUR

Hangzhou Tigermed Consulting Co., Ltd (5HZ1.F)

Compare
2.8400
-0.0800
(-2.74%)
As of 3:29:02 PM GMT+2. Market Open.
Loading Chart for 5HZ1.F
  • Previous Close 2.9200
  • Open 2.8200
  • Bid --
  • Ask 3.1000 x --
  • Day's Range 2.8200 - 2.9000
  • 52 Week Range 2.7800 - 5.1000
  • Volume 265
  • Avg. Volume 7
  • Market Cap (intraday) 4.511B
  • Beta (5Y Monthly) 0.92
  • PE Ratio (TTM) 47.33
  • EPS (TTM) 0.0600
  • Earnings Date Apr 23, 2025 - Apr 28, 2025
  • Forward Dividend & Yield 0.07 (2.09%)
  • Ex-Dividend Date Jun 7, 2024
  • 1y Target Est --

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. In addition, the company offers patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety, bioequivalence, and third-party training services, as well as chemistry, management, and controls services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

www.tigermedgrp.com

10,185

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 5HZ1.F

View More

Performance Overview: 5HZ1.F

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

5HZ1.F
22.40%
SSE Composite Index (000001.SS)
4.92%

1-Year Return

5HZ1.F
6.70%
SSE Composite Index (000001.SS)
4.54%

3-Year Return

5HZ1.F
62.45%
SSE Composite Index (000001.SS)
2.00%

5-Year Return

5HZ1.F
81.59%
SSE Composite Index (000001.SS)
12.77%

Compare To: 5HZ1.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 5HZ1.F

View More

Valuation Measures

Annual
As of 4/8/2025
  • Market Cap

    4.64B

  • Enterprise Value

    4.73B

  • Trailing P/E

    49.56

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.04

  • Price/Book (mrq)

    0.97

  • Enterprise Value/Revenue

    5.71

  • Enterprise Value/EBITDA

    33.37

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.14%

  • Return on Assets (ttm)

    2.16%

  • Return on Equity (ttm)

    1.85%

  • Revenue (ttm)

    6.6B

  • Net Income Avi to Common (ttm)

    405.14M

  • Diluted EPS (ttm)

    0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.14B

  • Total Debt/Equity (mrq)

    11.77%

  • Levered Free Cash Flow (ttm)

    245.02M

Research Analysis: 5HZ1.F

View More

Company Insights: 5HZ1.F

Research Reports: 5HZ1.F

View More

People Also Watch